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Abstract: Cells constantly adapt their metabolic pathways to meet their energy needs and respond
to nutrient availability. During the last two decades, it has become increasingly clear that NAD+,
a coenzyme in redox reactions, also mediates several ubiquitous cell signaling processes. Protein
ADP-ribosylation is a post-translational modification that uses NAD+ as a substrate and is best known
as part of the genotoxic stress response. However, there is increasing evidence that NAD+-dependent
ADP-ribosylation regulates other cellular processes, including metabolic pathways. In this review, we
will describe the compartmentalized regulation of NAD+ biosynthesis, consumption, and regeneration
with a particular focus on the role of ADP-ribosylation in the regulation of glucose metabolism in
different cellular compartments.
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1. Introduction
1.1. NAD+ in Redox Reactions
Metabolic pathways are tightly regulated on various levels, which include co-enzyme availability,
allosteric regulation with various metabolic intermediates, and post-translational modification of
metabolic enzymes. Nicotinamide adenine dinucleotide (NAD+, in its oxidized state) is a vital small
molecule, best known as a cofactor that regulates metabolism through its electron transfer function in
redox reactions that regulate glycolysis, tricarboxylic acid (TCA) cycle, and oxidative phosphorylation
driven energy metabolism [1–3]. In redox reactions, NAD+ is reversibly reduced to NADH [4]. NAD+
can be regenerated in the cytoplasm from NADH through the conversion of pyruvate to lactate by the
lactate dehydrogenase (LDH), thereby maintaining active aerobic glycolysis [5]. Alternatively, electrons
from NADH can enter the mitochondrial electron transport chain via the glycerol-3-phosphate or
the malate-aspartate shuttle [6,7]. Within the mitochondria, NAD+ plays a central role by carrying
high-energy electrons and driving oxidative phosphorylation [8]. NAD+ accepts electrons from different
sources and transfers them to complex I of the electron transport chain, which results in the generation
of ATP. The maintenance of NAD+ levels, as well as the NAD+/NADH ratio, is crucial for mitochondrial
homeostasis and ATP production.
1.2. Cellular NAD+ Pools
The in-vivo half-life of NAD+ varies between 15 min and 15 h depending on the tissue [9].
Decreased NAD+ levels dampen the activities of NAD(H)-dependent enzymes involved in oxidative
phosphorylation, TCA cycle, and glycolysis, which lowers the ATP production [10]. Several approaches
have been developed to try to quantify NAD+ availability in different subcellular compartments.
Cells 2019, 8, 890; doi:10.3390/cells8080890 www.mdpi.com/journal/cells
Cells 2019, 8, 890 2 of 23
Compartment-targeted expression of the catalytic domain of ADP-ribosyltransferase diphtheria
toxin-like 1 (ARTD1, formerly called PARP1) has been used as a molecular detector of NAD+ because
formation of poly-ADP-ribose, which can be detected by immunofluorescence, functions as a proxy for
NAD+ availability [11,12]. In addition, NAD+ metabolite tracing methods have been developed that
quantify NAD+ and NADH levels, and define how their ratios in different subcellular compartments
under several stress conditions change [11,13–15]. Free NAD+ has been measured in almost all
organelles, including the mitochondria, peroxisomes, the endoplasmic reticulum (ER), and the Golgi
complex [11–13]. These measurements have revealed that steady state NAD+ concentrations, as well as
changes in NAD+ concentrations in response to different stimuli, vary considerably between different
subcellular compartments. Hence, NAD+ dynamics seem to be compartment specific. Furthermore,
these dynamics also vary depending on the cell type, stress, and redox status as well as metabolic
fitness [16]. The NAD+ concentrations are highest in the mitochondria (approx. 400 µM, 40%–70% of
the total cellular NAD+ pool [17,18]), intermediate in the nucleus and cytoplasm (approx. 100 µM)
and low (<1 µM) in the extracellular space [13,15,19]. Cytoplasmic and nuclear NAD+/NADH ratios
are typically between 60 and 700 in eukaryotes depending on the cell type, while the mitochondrial
ratio is much lower at around 7–8 [20,21]. Nuclear and cytoplasmic NAD+ pools are interconnected as
NAD+ levels in both compartments are generally comparable and NAD+ precursors freely diffuse
through the nuclear pore complex. In contrast, NAD+, NADH and NAD+ precursors cannot freely
diffuse across mitochondrial membranes, and thus mitochondrial NAD+ pools are more isolated [22].
This compartmentalization of NAD+-levels provides a special level of regulation and sophistication
that requires tightly regulated expression of enzymes involved in NAD+ biogenesis.
1.3. NAD+ Biogenesis/Synthesis
NAD+ is constantly synthesized, degraded, and recycled, not only in the cytoplasm where most
research is focused, but also within major organelles including the nucleus, Golgi, and peroxisomes [23,24].
In mammals, NAD+ is generated either de-novo via the kynurenine pathway from tryptophan, via the
Preiss-Handler pathway from nicotinic acid (NA), via the salvage pathway from nicotinamide (NAM),
or via the nicotinamide ribose kinase pathway from nicotinamide riboside (NR) [25–28]. Many enzymes
involved in the biosynthesis of NAD+ are highly compartmentalized on the subcellular level and tightly
regulated on the transcriptional level, which provides the rationale as to why some tissues and/or cell
types are able to synthesize NAD+ from certain sources and others are not. A detailed overview of the
NAD+ metabolic pathways has been extensively described in other reviews [1,25,29,30].
In-vivo, the de-novo synthesis of NAD+ from tryptophan takes place predominantly in the liver.
The liver then excretes NAM which is subsequently taken up by other organs and converted to
NAD+. NAD+ fluxes vary widely across tissues, with high fluxes in the small intestine and spleen
and low fluxes in skeletal muscle [9]. Intravenous administration of NR or NMN delivered NAD+
to multiple tissues, but the same agents given orally were metabolized to NAM, indicating that the
type of administration and the involved organs metabolize NAD+ precursors differently [9]. In-depth
analysis of NAD+ synthesis-breakdown fluxes in different cell lines revealed that the vast majority
of immortalized cells lack the enzymes to synthesize NAD+ from tryptophan, and thus they depend
entirely on NAM [9]. Consequently, most cell lines depend on two enzymes to generate NAD+. The first
is nicotinamide phosphoribosyltransferase (NAMPT) which catalyzes the conversion of NAM to NMN;
this is considered the rate limiting step of the NAD+ salvage pathway [31]. The second family of enzymes
required are the nicotinamide mononucleotide adenylyltransferases (NMNATs), which convert NMN
to NAD+. NAMPT is primarily nuclear and cytosolic; however, a small portion co-purifies with
mitochondria isolated from the liver [32]. There are both intracellular and extracellular isoforms of
NAMPT that are known as iNAMPT and eNAMPT, respectively [33]. Three isoforms of NMNAT have
been identified; NMNAT1 localizes to the nucleus, NMNAT2 to the Golgi apparatus and neuronal
axons, and NMNAT3 to the mitochondria [34–36]. Given that both NAMPT and NMNAT3 localize to
the mitochondria, it has been suggested that mitochondria might recycle their own nicotinamide or
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take it up from the cytoplasm. Increasing evidence has revealed that (i) reduced NAD+ levels alter
metabolic rates and increase age-related disease susceptibility and (ii) restoration of NAD+ levels can
prevent disease progression [37,38].
1.4. NAD+ Signaling
Within a given location, NAD+ has two main pools, the free pool and protein-associated pool.
Moreover, the ratio of these pools varies across different organelles, cell types, and tissues [29].
NAD+ is predicted to bind >500 proteins involved in the regulation of almost all major biological
processes [39,40]. Two principal types of NAD+-dependent signaling reactions have recently been
described: the generation of second messenger molecules and the modification of proteins [41,42].
NAD+ is a direct precursor of various small molecules such as ADP-ribose (ADPr), cyclic ADP-ribose
(cADPr), NAADP and O-acetyl-ADP-ribose (OAADPR); all of which are important second messengers
that regulate multiple aspects of biology, including cell survival, apoptosis, and inflammation [39,43–48].
In addition, NAD+ serves as a substrate for post-translational protein modifications (PTM). In mammals,
the two main NAD+-dependent enzyme families are the ADP-ribosyltransferases (ARTs) and the
sirtuins (SIRTs) [39,49–52]. Both protein families use NAD+ as a co-substrate to modify or de-modify
target proteins. Interestingly, ADP-ribosylation was the first NAD+-dependent PTM identified [53].
ADP-ribosylation involves the attachment of one (mono-ADP-ribosylation; MARylation) or several
(poly-ADP-ribosylation; PARylation) moieties of ADPr onto specific amino acid acceptor sites of target
proteins or onto ribonucleotides [54]. Depending on their structural similarities to either cholera- or
diphtheria toxins, ARTs can be further subdivided into the intracellular ARTDs (Diphteria toxin-like)
and the extracellular or membrane-associated ARTCs (Cholera toxin-like). Despite the very low
NAD+ concentrations in these compartments [55], ARTCs as well as cADPr hydrolases, such as
CD38, can metabolize NAD+ in the extracellular space and in serum. Since this review focuses
on the influence of ADP-ribosylation on carbohydrate metabolism the reader is referred to other
reviews describing extracellular NAD+ consumption [45,56]. SIRTs remove acyl marks (most commonly
acetylation) from proteins using NAD+ as an acceptor, thereby generating OAADPR and NAM [39,57].
SIRTs and ARTs localize to various intracellular compartments and have been experimentally linked
to distinct cellular functions. Both enzyme families are associated with the regulation of various
physiological processes, including metabolic regulation, DNA damage repair, cell cycle progression,
and epithelial-to-mesenchymal transition (EMT) [58–62].
It is important to note that when functioning as a coenzyme, for instance in redox reactions,
NAD+ is reversibly converted to NADH. In contrast, when NAD+ functions as a signaling molecule
in NAD+-dependent signaling processes, NAD+ but not NADH, is used as a substrate [63] and is
continuously and irreversibly catabolized by cleavage of the glycosidic bond between NAM and
the ADPr moiety. In cells, the involvement of NAD+ in deacetylation reactions or ADP-ribosylation
requires constant re-synthesis of NAD+ to avoid depletion of intracellular NAD+ pools, which is
particularly challenging for rapidly dividing cells [9].
NAM and ADPr are the common products generated as a result of NAD+-dependent signaling
conversions. In human cells, ADPr can be cleaved by several members of the Nudix hydrolase
family [64]. Among these enzymes, NUDT9 appears to have the highest specificity towards ADPr
generating AMP and ribose 5-phosphate [65–67]. The recycling of these degradation products would
require three molecules of ATP to regenerate NAD+. Therefore, NAD+-dependent signaling events,
especially PARylation, are rather energy consuming.
1.5. ADP-Ribosylation and Carbohydrate Metabolism
ADP-ribosylation is considered energetically challenging for the cell, as each ADPr moiety
attached to a given target protein requires the consumption of one NAD+ molecule. Therefore,
ADPr-metabolizing enzymes such as ARTs and ADP-ribosylhydrolases (ARHs) have a very strong
impact on intracellular NAD+ homeostasis [9]. Indeed, an anti-correlation between the activity of
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the predominant nuclear ART, ARTD1, and intracellular NAD+ levels has been the subject of various
studies [68–72]. It is, thus, not surprising that ART activation has been linked to cell metabolism in
various physiological and pathophysiological processes, including adipogenesis, genotoxicity-induced
cell death, immune cell activation, and metabolic disorders [68–73]. In fact, the activity of these
enzymes can influence glycolysis and oxidative phosphorylation directly and indirectly at various
steps (see below). NAD+ and NADH are important redox-equivalents for various metabolic reactions,
like the conversion of pyruvate to lactate or the conversion of succinate to fumarate and back (Figure 1).
In addition, ADP and ATP are important co-factors as their ratio is strongly dependent on oxidative
phosphorylation and, thus, NAD+. As a consequence, extensive ART activation decreases NAD+ and
ATP levels, and indirectly influences anabolic and catabolic reactions involved in central carbohydrate
metabolism. There is, however, growing evidence that ARTs also regulate the carbohydrate metabolism
by directly modifying important regulators of the involved metabolic pathways. ADP-ribosylation has
also been proposed to play a role in other metabolic processes, such as the lipid metabolism (reviewed
in [74]). ADP-ribosylated proteins involved in glycose metabolism with assigned ADPr amino acid
acceptor sites are summarized in Table 1.
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Figure 1. Schematic overview over the main metabolic hubs comprising the central carbohydrate
metabolism. Gycolysis, TCA cycle and oxidative phosphorylation are depicted in black (black arrows),
while enzymes involved in those processes are depicted in dark blue. NAD+ metabolism, including
synthesis and consumption is depicted in green (green descriptions and arrows), while ADP/ATP
conversions are depicted in light blue. Glucose-6-phosphate (Glucose-6-P), fructose-6-phosph te (Fruct se-
6-P), fructose-1,6-bisphosphate (Fructose-1,6-BP), glyceraldehyde-3-phosphate (Glyceraldehyde-3-P),
oxaloactetate (OAA), isocitrate (Isoc), a-ketoglutarate (a-KG), succinate (Succ), fumarate (Fum), malate
(Mal), hexokinase (HK), phosphoglucoisomerase (PGI, phosphofructokinase (PFK), aldolase (FBA),
lactate dehydrogenase (LDH), pyruvate dehydrogenase (PDH), glutamate dehydrogenase (GDH),
insulin receptor (IR), insulin receptor signaling (IRS).
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Table 1. Overview of ADP-ribosylated proteins involved in glucose metabolism with assigned ADP-ribose
amino acid acceptor site and their function.
Protein Modification Side Function Function Affectedby ADPR Localization References
ATP5A1 E508, K506 (m)S184, S513 (h) ATP synthesis N/A m [75,76]
ATP5B E98, R121 (m) ATP synthesis N/A m [75]
ATP5F1 H164, S226 (h) ATP synthesis N/A m [76]
ATP5F1B S415, R458, H477 (h) ATP synthesis N/A m [76]
ATP5F1C S195 (h) ATP synthesis N/A m [76]
ATP50 R29, S126 (m)S163, S166 (h) ATP synthesis N/A m [75,76]
C/EBP-b E135, K133, E139 (m)S141, S257 (h)
Transcription factor,
gene expression
Yes
(activity dampened) n [76,77]
COX4I1 H51 (h) Electron transport chain N/A m [76]
CYCS S34 (h) Electron transport chain N/A m [76]
GAPDH R198, R232 (m)R80, S122, S192, R197, S210 (h) Glycolysis N/A c, n [75,76]
MDH1 S241 (h) Carbohydrate metabolism N/A m [76]
MDH2 S261, S246 (m)S317 (h) Carbohydrate metabolism N/A m [75,76]
NDUFB1 R49 (m) Electron transport N/A m [75]
NDUFB5 R93 (m) Electron transport N/A m [75]
NDUFAF7 R415 (m) Electron transport N/A m [75]
NDUFC2 R120 (m) Electron transport N/A m [75]
NDUFAB1 S99 (h) Electron transport N/A m [76]
NDUFV1 R449 (m) Electron transport N/A m [75]
PDPR R866 (m) Carbohydrate metabolism N/A m [75]
PDHA1 R304 (m) Carbohydrate metabolism N/A m [75]
PDHX S131 (m) Carbohydrate metabolism N/A m [75]
SDHA S505, H522 (h) Electron transport N/A m [76]
UQCRC1 S221 (h) Electron transport N/A m [76]
UQCRC2 R241 (m)S221 (h) Electron transport N/A m [75,76]
UQCRFS1 E95 (m) Electron transport N/A m [75]
Abbreviations: R: arginine, S: serine, K: lysine, H: histidine, E: glutamic acid, c: cytoplasm, m: mitochondria, n:
nucleus, (m): mouse, (h): human, N/A: not available.
2. Cytoplasmic Crosstalk of ADP-Ribosylation and the Carbohydrate Metabolism
2.1. Cytoplasmic NAD Biosynthesis
Many enzymes involved in NAD+ biosynthesis, such as NAMPT and the NMNATs, and
breakdown, like the ARTs and SIRTs, are highly compartmentalized on the subcellular level, providing
yet another layer of NAD+ level regulation ([16]; Table 2).
The enzymes involved in the kynurenine and the Preiss-Handler pathway all localize to the
cytoplasm. Therefore, de-novo NAD+ synthesis predominantly happens in this compartment. With
NAMPT and NMNAT2 the cytoplasm also harbors a set of enzymes required for NAD+ recycling
from NAM and NMN. As mentioned, for most transformed cells the salvage pathway is the main
source of NAD+ synthesis. In those cells, the levels of NAMPT are highly dynamic and respond to
changes in cellular demands for NAD+, such as starvation or severe DNA damage, for instance [32].
NMNAT2 catalyzes the final reaction, converting NMN to NAD+ in the cytoplasm. In the cytoplasm,
NAD+ plays an important electron carrier role in the glycolysis, as it is required for the conversion of
glyceraldehyde-3-phosphate to 1,3-biosphosphoglycerate, as well as for the conversion of pyruvate to
lactate. In fact, reductions in cytoplasmic NAD+ levels are associated with reduced glycolysis and the
necessity of cells to metabolize non-glucose carbon sources, such as glutamate or pyruvate via the TCA
cycle [78].
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Table 2. Overview of the localization of enzymes involved in NAD+ synthesis and conversion.
Nucleus
Family Name NAD+ Metabolism ART/ARH Activity References
ARTs ARTD1 Consumption Poly (branching) [79–81]
ARTD2 Consumption Poly (branching) [79–81]
ARTD3 Consumption Mono [79–81]
ARTD4 Consumption Mono [79–81]
ARTD5 Consumption Poly/Oligo [79–81]
ARTD6 Consumption Poly/Oligo [79–81]
ARTD8 Consumption Mono [79–81]
ARTD9 Consumption Inactive/Mono [79,80,82]
ARTD10 Consumption Mono [79–81]
ARTD11 Consumption Mono [79–81]
ARTD14 Consumption Mono [79–81]
ARHs PARG Poly [83,84]
ARH3 Poly/Mono [85–87]
TARG Mono [88–90]
SIRTs SIRT1 Consumption N/A [39]
SIRT2 Consumption N/A [39]
SIRT6 Consumption Mono [39,91]
SIRT7 Consumption N/A [39]
NAMPT NAMPT Synthesis N/A [2]
NMNAT NMNAT1 Synthesis N/A [2]
Cytoplasm
Family Name NAD+ Metabolism ART/ARH Activity References
ARTs ARTD2 Consumption Poly (branching) [79–81]
ARTD3 Consumption Mono [79–81]
ARTD4 Consumption Mono [79–81]
ARTD5 Consumption Poly/Oligo [79–81]
ARTD6 Consumption Poly/Oligo [79–81]
ARTD7 Consumption Mono [79–81]
ARTD8 Consumption Mono [79–81]
ARTD9 Consumption Inactive/Mono [79,80,82]
ARTD10 Consumption Mono [79–81]
ARTD11 Consumption Mono [79–81]
ARTD12 Consumption Mono [79–81]
ARTD13 Consumption Inactive [79–81]
ARTD14 Consumption Mono [79–81]
ARTD15 Consumption Mono [79–81]
ARTD16 Consumption Mono [79–81]
ARTD17 Consumption Mono [79–81]
ARTD18 Consumption Mono [79–81]
ARHs PARG Poly [83,84]
ARH1 Mono [85]
ARH2 Inactive [85]
MacroD2 Mono [88–90]
SIRTs SIRT1 Consumption N/A [39]
SIRT2 Consumption N/A [39]
NAMPT NAMPT Synthesis N/A [2]
NMNAT NMNAT2 Synthesis N/A [2]
Mitochondria
Family Name NAD+ Metabolism ART/ARH Activity References
ARTs ARTD1 Consumption Poly (branching) [79,80]
ARHs PARG Poly [83,84,92]
ARH3 Poly/Mono [85–87]
MacroD1 Mono [88–90,93]
SIRTs SIRT3 Consumption N/A [39]
SIRT4 Consumption Mono [39,94]
SIRT5 Consumption N/A [39]
NAMPT NAMPT Synthesis N/A [2]
NMNAT NMNAT3 Synthesis N/A [2]
Abbreviations: ART: ADP-ribosyltransferase, ARH: ADP-ribosylhydrolase, SIRT: Sirtuin, NAMPT: Nicotinamide
phosphoribosyltransferase, NMNAT: Nicotinamide mononucleotide adenylyltransferase, N/A: Not available
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2.2. Cytoplasmic ADP-Ribosylation
Many ARTD-family members, especially ARTDs catalyzing MARylation are described to localize
to the cytoplasm (Table 2) [49]. Nonetheless, potential functions of ADP-ribosylation in the cytoplasm
are rather poorly described. The best-studied ARTDs localizing to the cytoplasm are ARTD10, ARTD12,
ARTD15 and the tankyrases (TNKs) [95–100]. ARTD10 and the TNKs have been linked to cytoplasmic
metabolic processes, while the other cytoplasmic ARTDs have thus far not been directly associated
with cell/carbohydrate metabolism. ARTD12 localizes to the Golgi and is involved in protein sorting
and trafficking [95,96], while ARTD15 localizes to the ER and has been linked to the unfolded protein
response [97,98]. For more detailed information about the function of other (cytoplasmic) ARTs, the
reader is referred to other reviews [101]. Nothing has so far been reported regarding the regulation of
the carbohydrate metabolism by cytoplasmic ARHs.
2.3. Crosstalk with Enzymes of the Carbohydrate Metabolisms
Glut4: Glut4 is one of 14 Glut transporters described in mammals [102]. Glut transporters
are transmembrane proteins that are able to transport hexoses from the extracellular space into
cells. Specifically, Glut4 transports glucose and glucosamine, and is predominantly expressed in
adipocytes, skeletal muscle and cardiomyocytes [102,103]. While some glucose transporters, such as
Glut1, constitutively localize to the cell membrane, Glut4 translocates to the plasma membrane in
response to insulin stimulation [103]. Both TNK1 and TNK2 have been shown to influence Glut4
mediated glucose transport in an ADP-ribosylation-dependent manner [99,104]. While in adipocytes,
tnks deficiency increased Glut4 levels, TNKs inhibition in myocytes destabilized Glut4 regulatory
proteins, resulting in decreased Glut4 translocation to the plasma membrane [99,104]. However, in both
studies tnks deficiency/inhibition affected insulin sensitivity. Furthermore, the use of TNK inhibitors
supported the notion that this process is dependent on ADP-ribosylation; specific target proteins of
TNK1/2, however, have not yet been identified.
Hexokinase 1: Hexokinases catalyze the initial step of glycolysis by converting glucose to
glucose-6-phosphate (Figure 2). In mammals, 4 isoenzymes, HK1, 2, 3, and 4 have been identified [105].
HK1 was shown to contain a PAR binding motif (PBM) that enables the enzyme to interact with PAR in
a non-covalent manner [106]. Under normal conditions HK1 localizes to the mitochondrial membrane.
Binding of HK1 to free cytoplasmic PAR, e.g., in the context of ARTD1 hyperactivation upon severe
genotoxic stress, was proposed to lead to the segregation of HK1 from the mitochondria and to
reduce its enzymatic activity in a dose-dependent manner, consequently slowing down glycolysis and
oxidative phosphorylation [106]. This observation was strengthened by the observation that inhibition
of PAR release by PARG knockdown rescued HK1 activity and the cells’ metabolic capacity. Together,
the above-discussed study proposes a mechanism in which extensive nuclear ARTD1-mediated PAR
formation results in a reduction in the enzymatic activity of HK1, which is independent on direct
ADP-ribosylation, but mediated via PAR binding.
Glycogen synthase kinase 3b: The glycogen synthase kinase 3b (GSK3b) has also been proposed
to be regulated by ADP-ribosylation [100]. GSK3b is a serine-threonine-kinase that regulates glucose
metabolism by controlling the activity of various enzymes involved in anabolic and catabolic carbohydrate
metabolism, including the glycogen synthase, the insulin receptor, the glucose-6-phosphatase, and/or
the phosphoenolpyruvate carboxykinase [107,108] (Figure 2). A recent study identified GSK3b as
a direct ADP-ribosylation target of ARTD10 [100]. Intriguingly, studies also suggest that ARTD10
negatively regulates cell metabolism and mitochondrial function, as ARTD10 knockdown increased
the respiratory capacities of various cell lines and reduced reactive oxygen species susceptibility via
induction of antioxidant gene expression [109]. In addition, ARTD10 levels were also shown to change
in response to fasting-induced metabolic stimulation [109]. A direct link between ARTD10-mediated
ADP-ribosylation and cell metabolism, however, remains to be elucidated.
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Glyceraldehyde 3-phosphate dehydrogenase: Another key-metabolic enzyme directly regulated via
ADP-ribosylation is the glyceraldehyde 3-phosphate dehydrogenase (GAPDH). GAPDH possesses
glyceraldehyde 3-phosphate dehydrogenase activity as well as nitrosylase activity. The enzyme plays an
important role in glucose breakdown by converting glyceraldehyde-3-phosphate to 1,3-bisphosphoglycerate;
a reaction that requires the reduction of NAD+ to NADH (Figures 1 and 2). Since the second activity is
linked to nuclear processes, the enzyme is considered a moonlighting enzyme [110,111]. Comparable
to GSK3b, ADP-ribosylation of GAPDH ha be n shown t decrease its enzymatic activity. While
initial studies suggested that GAPDH auto-ADP-ribosylates itself [112], more recent studies suggest
GAPDH to rather be trans-ADP-ribosylated by either ARTD1 or ARTD10 [113,114]. ARTD1-mediated
inhibition of GAPDH has been demonstrated in the context of hyperglycemia, where increased glucose
concentrations in the cell culture medium resulted in increased DNA double-strand breaks as a
consequence of an increase in mitochondrial superoxide production [113]. GAPDH inhibition could
further be associated with an increase in PKC activity, as well as NF-κB activation; both of which
are likely indirect responses to the increase in DNA-damage. In addition, increased etabolic flux
into the hexosamine pathway was also observed as a possible consequence to reduced glycolysis
rates [113]. Decreasing mitochondrial superoxide production (e.g., via overexpression of UCP-1 or
mtSOD2) rescued all of the above-described consequences of hyperglycemia. Besides ARTD1, also
ARTD10 was shown to interact with GAPDH [114]. Overexpression of full-length ARTD10 or its
catalyti domain lead to an ADP-ribosylation-d pendent s questering of GAPDH in membrane-free,
cytoplasmic cell bodies [114]. The functional consequence of this ARTD10-mediated ADP-ribosylation,
as well as compartmentalization of GAPDH, has however so far not been further investigated.
3. Mitochondrial NAD Biosynthesis, ADP-Ribosylation Crosstalk and Carbohydrate Metabolism
3.1. Mitochondrial NAD Biosynthesis
Supplementing cell culture medium with NAD+ or NR has been shown to increase mitochondrial
NAD+ levels in cultured cells [36,115,116]. Intra-mitochondrial NAD+ has been described to be
synthesized from NAM [32,117] or NMN via NMNAT3 [118]. In agreement with this hypothesis,
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a mitochondrial localized splice variant of NMNAT3 has been identified and ectopically expressed
NMNAT3 shown to localize to the mitochondria [36]. Although one study suggested that NMNAT3
overexpression increased mitochondrial NAD+ [119], other studies reported that NMNAT3 was not
required for mitochondrial NAD+ level maintenance [10,120]. Mitochondrial NAD+ levels vary in
a circadian fashion and have been shown to directly influence fuel selection [121] and regulate cell
survival under stress conditions [32]. Although cytoplasmic and mitochondrial NAD+ pools are
indirectly connected via glycolysis and oxidative phosphorylation [122], very recent evidence has been
presented using isotopic labeling of NR and NAR which suggest a direct NAD+ transport between
these two intra-cellular spaces [123]. It is, therefore, possible that mitochondrial NAD+ comes from
both, local synthesis and transport from the cytoplasm; each of these sources are likely to serve as
the backup for the other, with both coordinately contributing to the tightly regulated and maintained
NAD+ concentrations within mitochondria.
3.2. Mitochondrial ADP-Ribosylation
High NAD+ concentrations within the mitochondria suggest that these organelles harbor ideal
conditions for protein ADP-ribosylation to take place [29]. In fact, the concept of mitochondrial
ADP-ribosylation was proposed over 30 years ago when a macromolecular enzymatic product of NAD+
was detected in mitochondria isolated from rat livers [117]. This, as well as several follow-up studies,
further described ARTs and ADP-ribosylhydrolase (ARHs) activities in mitochondrial lysates [117,124,125].
Unfortunately, these studies failed to identify the corresponding enzymes that mediated these activities.
Even the recent identification of the whole mitochondrial proteome did not result in the clear detection
of any known ARTs in this organelle [126]. While the distribution of ARTs and ARHs in nucleus
and cytoplasm has been quite well described, the existence and distribution of ADP-ribosylating
enzymes in mitochondria remains thus controversial. Five enzymes able to regulate ADP-ribosylation
have so far been associated with mitochondria: SIRT4 [94,127], ARTD1, PARG, ARH3 [92,128], and
MacroD1 [93,129]. ART activity has, in fact, been detected in the mitochondrial matrix, as well as
the inner- and outer mitochondrial membranes [130]. Due to the lack of clear evidence regarding
mitochondrial localized ARTs and ARHs, this review briefly summarizes what is known about the five
enzymes SIRT4, ARTD1, PARG, ARH3, and MacroD1 with respect to mitochondria:
SIRT4: In mammals, 7 SIRTs have been described, 3 of which (namely, SIRT3, 4, and 5) localize to
the mitochondria (Table 2) [131–133]. Interestingly, SIRT4 has been described to not only hydrolyze
protein bound acyl-groups, but to also possess ADP-ribosylation activity [94]. Indeed, SIRT4 was
described to ADP-ribosylate and thus negatively regulate the activity of the glutamate dehydrogenase
(GDH) in-vitro and in pancreatic β-cells, suggesting SIRT4 as an important regulator of insulin
secretion [94,127]. GDH is, however, the only protein thus far described to be ADP-ribosylated
by SIRT4 (Figure 3). Recent mass-spectrometry-based analyses identified various ADP-ribosylated
mitochondria-localized proteins, thus further strengthening the idea that the mitochondria harboring
several enzymes with ADP-ribosylating activities [75,76,134].
ARTD1: ARTD1s mitochondrial localization is the subject of controversial discussions in the field
of ADP-ribosylation. This stems from the fact that ARTD1 does not contain a classical mitochondrial
localization sequence and, thus, it has been proposed that its translocation is dependent on an association
with mitofillin [135]. This association, however, would not explain how ARTD1 would be able to enter
mitochondria. While some studies detected ARTD1 in mitochondria, mostly via western-blot analysis;
other studies clearly only detect ARTD1 in the nucleus [135–144]. Due to the high abundance of ARTD1,
western-blot analysis after cell fractionation (e.g., mitochondrial isolation) should to be taken with caution.
Moreover, given that the proposed protein targets of mitochondria-localized ARTD1 (mtPARP1) mainly
localize to the mitochondrial matrix, more thorough mitochondrial fractionations (including detergent
lysis) are required to clarify if and where ARTD1 localizes within the mitochondria. Mitochondrial
localization of ARTD1 has been proposed to regulate the mitochondrial energy homeostasis [92,139]
(i.e., mitochondrial oxidative capacity) and mitochondrial DNA damage repair [145]. PARP inhibition or
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deletion of ARTD1 in different cell lines and systems has been shown to increase mitochondrial oxygen
consumption rate [92]. Nevertheless, determining whether ARTD1 needs to localize to mitochondria
for these effects requires further experimental investigation. In fact, since nuclear ARTD1 has also been
demonstrated to affect whole cell NAD+ homeostasis [106], all metabolic phenotypes attributed to
mitochondrial-localized ARTD1 might well be indirect consequences of the nuclear ARTD1 (see below,
nuclear compartment).Cells 2019, 8, x 10 of 24 
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PARG: PARG is able to degrade poly-ADP-ribose [146]. Two shorter splice variants of PARG have
been described to reside in the extra-nuclear space [92]. One of these shorter forms contains a predicted
N-terminal mitochondrial localization sequence, but direct evidence demonstrating that this isoform of
PARG localizes to the mitochondria remains missing. Nevertheless, overexpression studies targeting
exogenous PARG (∆1-460) to mitochondria indicated that this PARG splice variant is inactive [92,128].
ARH3: ARH3 has recently been shown to hydrolyze both PARylation and MARylation [86,87].
While the majority of ARH3 localizes to the nucleus, a small fraction of the hydrolase has also been
detected in mitochondria [86,87]. In contrast to PARG, overexpression of mitochondria-targeted
ARH3 reduced mitochondrial protein ADP-ribosylation, thus suggesting that ARH3 might indeed be
involved in mitochondrial ADPr metabolism [92,128]. Interestingly, while ARH3 could functionally
be associated to metabolic diseases in human and in mice [147,148], direct evidence for endogenous
mitochondrial ARH3, comparable to PARG, is still missing.
M croD1: MacroD1 has been shown to be act ve towards mono-ADP-ribosylated proteins, as
well as toward free OAADPR, the by-product of SIRT-catalyzed de-acetylation [88,89,129]. In contrast
to the four enzymes discussed above, MacroD1 has been clearly shown to predominantly localize
to mitochondria [93,129]. Available transcriptome data from humans, mice, and rats [149] suggest
that MacroD1 expression correlates with the energetic status of a given cell or tissue type. While the
expression of MacroD1 is rather moderate in most tissues, tissues with a high energetic turnover, like
the heart or skeletal muscl , express high ev ls f this hydrolase. In addition, several studies suggest
that MacroD1 plays a role in the regulation of adipogenesis and insulin receptor signaling [150,151].
Upon knockdown of MacroD1 in adipocytes, an increase in glucose uptake and PPARγ expression on
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both mRNA and protein levels was observed; which suggests that it could negatively affect adipocyte
differentiation. In addition, this knockdown was also shown to promote insulin signaling, which
resulted in increased Akt phosphorylation [150]. In contrast, overexpression of MacroD1 increased
ERK1/2- and Akt phosphorylation and insulin content in the pancreatic b-cell-derived MIN6 cell
line [151]. While the precise mode of action of MacroD1 remains elusive, it is possible that MacroD1
influences the activity of Akt and insulin signaling in a cell and stimuli specific manner. In fact, MacroD1
has been shown to alter cell proliferation and apoptosis [152], and has been linked to the degree of
differentiation and the invasiveness of various types of cancer [153]. The interesting associations of
MacroD1 with cell metabolism and metabolism-related diseases make this enzyme an attractive target
of further studies.
The function and relevance of mitochondrial ADP-ribosylated proteins is currently under
extensive debate. While some labs suggest mitochondrial ADP-ribosylation to be involved in the
regulation of metabolic enzymes, others propose that the modification regulate mitochondrial DNA
damage repair or oxidative stress responses [154]. Several recent proteomic studies identified
various mitochondria-localized proteins to be ADP-ribosylated in lysates from both cells and
mouse organs [75,76,134]. The amount of ADP-ribosylated mitochondrial proteins seemed especially
pronounced in mitochondria-rich tissues with high metabolic activities such as heart, skeletal muscle,
and brown adipose tissue. Nevertheless, detection of endogenous mitochondrial ADP-ribosylation
via other methods has thus far proven challenging. Various ADP-ribosylated mitochondrial proteins
are implicated in many different biological processes, including mtDNA repair, protein-, metabolite-
and ion transport, protein folding and synthesis, and mitochondrial metabolism. The function of
ADP-ribosylation in mtDNA repair, has however thoroughly been addressed in previous reviews [154].
As this review focuses mainly on carbohydrate metabolism, proteins involved in non-metabolic
processes will not further be discussed.
3.3. Crosstalk with Proteins or Enzymes of the Carbohydrate Metabolisms
Complex I, II, III, and the ATP-synthase: A prominent cluster of mitochondrial ADP-ribosylated
proteins is involved in the mitochondrial respiratory chain. Indeed, complex I, II, III, and the
ATP-synthase have been shown to be ADP-ribosylated and harbor various potential ADPr acceptor
sites [75] (Figure 3). Several studies, including an in-vivo ischemia reperfusion (or traumatic brain
injury model) and in vitro activation of the nitric-oxide synthase, provided evidence that the induction
of ADP-ribosylation dampens mitochondrial oxidative phosphorylation [136,137,139,155]. While some
of the studies directly showed different sub-units of different respiratory chain complexes to be
ADP-ribosylated upon induction of the respective stress, other studies only observed an increase in
(mitochondrial) ADP-ribosylation in general.
Malate dehydrogenase (MDH), pyruvate dehydrogenase (PDH) and glutamate dehydrogenase (GDH):
In addition to the respiratory chain components, other mitochondrial metabolic enzymes involved in
carbohydrate metabolism, such as MDH, PDH or GDH were also found to be ADP-ribosylated [75,94,134].
While the functional contribution of ADP-ribosylation to MDH or PDH activities has not yet been
experimentally addressed, ADP-ribosylation of the GDH by SIRT4 has been proposed to dampen its
activity (see above) [94].
4. Crosstalk between Nuclear ADP-Ribosylation and the Carbohydrate Metabolism
4.1. Nuclear NAD Biosynthesis
The cytoplasmic NAD+ pool serves as a central hub that connects and regulates other NAD+ pools
(Figure 1). Cytosolic and nuclear NAD+ pools are closely connected as indicated by studies using the
small molecule NAMPT inhibitor FK866, which demonstrated comparable nuclear and cytoplasmic
reductions in NAD+ following treatment [13]. It is also expected that the NAD+ precursors, NAM and
NMN, are shared between nucleus and cytosol as they are able to freely diffuse through the nuclear
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pore complex. The final step, converting NMN to NAD+, is believed to be locally catalyzed. While
cytoplasmic NAD+ is mainly synthesized by NMNAT2, which localizes to the Golgi apparatus [35,156],
nuclear NAD+ is thought to be mainly synthesized by nuclear NMNAT1, the most ubiquitously
expressed NMNAT isoform [157,158]. Recent studies found that depleting NMNAT2 significantly
reduced cytoplasmic NAD+ but minimally affected nuclear NAD+. Furthermore, nuclear NAD+
could not completely replenish cytoplasmic NAD+ following NMNAT2 depletion [13]. Additionally,
NMNAT1 has been shown to be recruited to gene promoters targeted by ARTD1, to locally generate
NAD+ and support the catalytic activity of ARTD1 [69,158]. These observations suggest that while
nuclear and cytoplasmic NAD+ pools are interconnected, local regulation by NMNAT1 and NMNAT2,
respectively, still plays an important role in NAD+ homeostasis. This compartment-specific local
regulation of NAD+ biosynthesis seems highly important for controlling the enzymatic activities of
ARTs and SIRTs.
4.2. Nuclear ADP-Riboslyation
The nuclear role of NAD+ is mainly centered on ARTD-mediated ADP-ribosylation and SIRT-
mediated deacetylation. As ARTDs and SIRTs are NAD+-consuming enzymes, their activities require
quasi constant replenishment of nuclear NAD+, mainly through nuclear NMNAT1-mediated NAD+
synthesis [9]. Nuclear ARTDs can dampen the activity of SIRTs either directly via ADP-ribosylation or
indirectly via substrate competition. Given that nuclear ARTs, especially ARTD1, are able to consume
tremendous amounts of NAD+ upon hyperactivation, they can reduce the substrates/co-factors (NAD+,
ATP) of many metabolic enzymes. Three of the known ARTDs localize predominantly to the nucleus
(ARTD1, ARTD2 and ARTD3), while others shuttle between the cytoplasm and nucleus (ARTD4-6,
ARTD8-12, ARTD14) [159]. ARTD1 is the most well-characterized member of the ARTD family and
is best-known for its involvement in genotoxic stress responses and as a cleaved marker during
apoptosis [160]. ARTD1 however also regulates transcription by different mechanisms including the
binding and/or modification of transcription factors (see below), transcription co-factors or histones
and thus influencing highly organized chromatin structures [161–165]. Of the seven mammalian SIRTs,
SIRT1, 6 and 7 have all been shown to localized to the nucleus [57,166]. SIRT6 has been described
to be an ADP-ribosyltransferase [91] that directly modifies ARTD1 and BAF170 [167,168], the latter
of which is a subunit of BAF chromatin remodeling complex required for activation of a subset of
NRF2 responsive genes following oxidative stress [167]. The extensive network of ARTD and SIRT
proteins and their regulatory targets indicates the profound impact that nuclear NAD+ can have on
various cellular processes [29]. A direct link between the enzymatic activities of nuclear ARHs and the
metabolic state of the cell remains to be explored.
4.3. Crosstalk with Proteins Regulating the Expression of Enzymes Involved in the Carbohydrate Metabolisms
As most enzymes involved in carbohydrate metabolism reside in either the cytoplasm or
the mitochondria, nuclear ARTDs have a limited ability to influence their activity directly via
ADP-ribosylation. As discussed above, the exception is GAPDH, which is believed to shuttle between
the cytoplasm and nucleus in response to metabolic stimulation. Nevertheless, nuclear ARTDs may still
indirectly affect various metabolic enzymes; indeed, it is possible that they regulate the expression of
genes involved in metabolic processes, potentially via transcription factor ADP-ribosylation (see above).
C/EBP-b: C/EBP-b is an important transcription factor involved in various physiological processes
including embryonic development, immune responses, hematopoiesis, adipogenesis, and glucose
metabolism [169–171]. C/EBP-b is a direct target of ARTD1-mediated poly-ADP-ribosylation during
adipocyte differentiation [69] (Figure 4). In fact, ADP-ribosylation of C/EBP-b during adipogenesis
initiation results in its eviction from the DNA. In order to allow C/EBP-b to bind to and activate its target
genes during the initial phase of adipogenesis, the activity of ARTD1 had to be dampened via reduction
of local NAD+ [69]. Adipogenic signaling rapidly induces cytoplasmic NMNAT-2, which competed
with nuclear NMNAT-1 for the NMN leading to a reduction in nuclear NAD+ levels. The whole process,
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including the changes in cytoplasmic and nuclear NAD+ levels was dependent on glucose-uptake.
Interestingly, cells would still differentiate in a glucose-free medium if ARTD1 was knocked down,
pointing towards an interplay between ARTD1 activity, NAD+ availability, and glucose metabolism.
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NRF1: Nuclear respiratory factor 1 (NRF1) is a transcription factor that regulates cell growth and
metabolism by activating gene invo ved in mitochondrial biogenesis and function [172]. Together
with NRF2, NRF1 mediates nuclear- and the mitochondrial genome coordination by regulating the
expression of a cluster of nuclear DNA-encoded genes that localize to the mitochondria [172]. ARTD1
has been shown to form a complex with NRF1 i an ADPr-independent manner facilitating the
regul tion of its target genes [173] (Fig re 4). Although modification is not required for the inding
of NRF1 to ARTD1, its enzymatic activity seems to be important for NRF1 transcriptional activity.
While the functional contribution of NRF1 in the regulation of mitochondrial dynamics and function
is well described, the precise contribution of ARTD1 remains to be investigated. Nonetheless, as
ARTD1 activity does affect mitochondrial function and cell metabolism, it is interesting to speculate
t at ARTD1 interacts with NRF1 in an NAD+-dependent manner, and th t this interaction transmits
information about the metabolic status (i.e., NAD+ concentration/availability) of the cell betwe n
nucleus and mitochondria.
HIF1: Hypoxia-inducible factor (HIF) 1 is the key transcription factor that regulates gene expression
in response to hypoxia [174]. The family of human HIF transcription factors is composed of six members,
all of which respond to changes in oxygen availability [174]. Upon oxygen deprivation, HIF1 is stabilized
and regulates the adaptation of the cells toward hypoxi on the transcriptional level. Many genes
involved in this adaptation are metabolic, and this is bec use hypoxic conditions fo ce cells to rely on
glycolysis rather than oxidative phosphorylation [174]. Several studies have demonstrated that ARTD1
forms a complex with HIF1 and acts as a transcriptional co-activator for HIF1 target genes [175,176]
(Figure 4). Although HIF1 does not seem to be a direct target of ARTD1, this co-activation has been
shown to be ADP-ribosylation dependent, as treatment with PARP inhibitors impaired HIF1 target gene
activation [175,176].
SIRT1: SIRT1 is a nuclear e-acetylase involved in the transcriptional regulation of various
genes [177]. Expression and activation of SIRT1 is generally positively associated with whole cell
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NAD+ levels and longevity [177,178]. ARTD2 deficiency resulted in an increase in SIRT1 on mRNA
and protein level, suggesting that ARTD2 negatively regulates the activity of SIRT1 in cell lines and
mice [179–182] (Figure 4). In line with this, ARTD2-deficient cells and mice showed higher expression
levels of SIRT1 regulated genes, such as PGC-1a, and displayed increased mitochondrial biogenesis and
function [179]. Further, ARTD2-deficient animals were protected against diet-induced obesity [179].
Inversely, overexpression ofARTD2decreased SIRT1 levels and mitochondrial biogenesis [180]. The effect
of ARTD2 on SIRT1 was found to be NAD+ independent, thus excluding a NAD+ substrate competition.
KAP1: KRAB-associated protein 1 (KAP1) is an important regulator of chromatin organization
involved in numerous processes including embryogenesis, development, cell cycle progression, and
apoptosis [183]. KAP1 also plays a important role in the repression of LINE1 transposons that depends
on SIRT6-mediated ADP-ribosylation of KAP1 [184]. The association of SIRT6 to LINE1 loci and the
modification of KAP1 declines with age. However, the mechanism how KAP1ADP-ribosylation is
regulating cell metabolism remains to be investigated.
5. Intercompartmental NAD+ Cross-Talks after Genotoxic Stress
Many enzymes involved in glycolysis and oxidative phosphorylation require NAD+ or ATP as
co-factors for their reactions (Figures 1–3). Consequently, a decrease in cytoplasmic and/or mitochondrial
NAD+ levels, and subsequently a decrease in whole cell ATP levels, blocks various anabolic and catabolic
reactions due to co-factor deficiencies. Studies using either PARP-inhibitors (PARPi) or ARTD1-deficient
cells revealed an anti-correlation between ARTD1 activity and intracellular NAD+ levels under basal
conditions. Thus, implying that ARTD1 also consumes NAD+ under physiological conditions [9].
Hyperactivation of ARTD1, as observed following severe genotoxic stress, has also been associated
with a substrate competition-mediated decrease in SIRT1 activity [185]. While some studies mainly
observed a considerable drop in nuclear and cytoplasmic NAD+ levels following genotoxic stress,
other studies have also found that mitochondrial NAD+ levels drop under these conditions [68,72,106,186].
Several studies have further associated genotoxic stress induced ARTD1 activation with a drop
in ATP levels and glycolysis [68,72,186]. It is important to note that while some studies observed
mainly a decrease in glycolysis, other studies also observed reduced mitochondrial oxidative
phosphorylation [106]. Both phenotypes could not only be rescued via ARTD1 inhibition/knockout, but
also via NAD+-supplementation [68,72,186]. The fact that PARP inhibitor increased NAD+ levels in
mice, improved mitochondrial function, and protected against the effects of a high fat diet [187,188],
provides strong evidence for a intercompartmental cross-talk. Thus, two main hypotheses exist that
could explain how hyper-activation of ARTD1 affects cell metabolism: (i) studies describing a drop in
glycolysis suggest that severe genotoxic stress results in a metabolic switch from glycolysis to oxidative
phosphorylation, making cells dependent on mitochondria for energy/ATP production, or (ii) studies
demonstrating a reduction in both the glycolytic and TCA capacity point towards a general reduction
in cell metabolism following ARTD1 activation and subsequent NAD+ depletion. Along with the
first possibility, supplementation with non-glucose carbon sources, such as pyruvate or glutamate to
directly fuel the TCA cycle, rescued astrocyte cell death following MNNG treatment [68]. In fact, the
two hypotheses presented here are not mutually exclusive as the reduced cellular metabolic capacities
could be a direct function of the degree of ARTD1 activation. While mild activation of ARTD1 might
predominantly result in the depletion of cytoplasmic and nuclear NAD+ pools, more pronounced
activation might also considerably deplete mitochondrial NAD+. As a consequence, in the first instance,
cells would mainly experience a decrease in glycolysis as they would run out of cytoplasmic NAD+,
which is required for the conversion of glucose-3-phosphate to 1,3-bisphosphoglycerate. Following a
more pronounced drop in NAD+ levels, cells would experience further reductions in TCA capacity,
as well as in oxidative phosphorylation. Pyruvate and glutamate could reduce the severity of the
phenotype in both cases, as both metabolites are not exclusively metabolized within the mitochondria,
but can also be utilized by enzymes in the cytoplasm [78].
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Whether mitochondria, with their high NAD+ concentrations, also contribute to NAD+-regulated
processes in other cellular compartments requires additional investigation. However, increased
mitochondrial NAD+ promoted cell survival during genotoxic stress, which was regulated by the
mitochondrial SIRT3 and SIRT4 [32]. These data show that mitochondrial NAD+ is a major determinant
of apoptosis and shed new light on the influence of diet on organ physiology and disease.
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